NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction

NCT01025154

CompletedPhase 2

Sponsor: M.D. Anderson Cancer Center

Conditions: Acute Myeloid Leukemia

Interventions: Clofarabine, Idarubicin, Cytarabine

Countries: United States

The goal of this clinical research study is to learn if the combination of clofarabine, cytarabine, and idarubicin can help to control Acute Myeloid Leukemia (AML) in patients who are between the ages of 18 and 60 years old. The safety of this study drug combination will also be studied.

Eligibility overview

Sex: ALL

Age: 18 Years to 60 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

1. Diagnosis of AML (World Health Organization (WHO) classification)
2. Patients must be chemotherapy-naïve, i.e. not have received any prior cytotoxic chemotherapy for AML (with the exception of hydroxyurea). They could have received prior therapy with hypomethylating agents, targeted, or biological agents.
3. Age 18 to 60 years.
4. Eastern Cooperative Oncology Group (ECOG) performance status \</= 2.
5. Serum creatinine \</= 1.0 mg/dL; if serum creatinine \> 1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be \> 60 mL/min/1.73m\^2 as calculated by the Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73m\^2)=186 \* (serum creatinine)\^-1.154 x (age in years)\^-0.023 \* (0.742 if patient is female) \* (1.212 if patient is black), where SCr is serum creatinine measured in mg/dL. serum bilirubin \</= 1.5 \* upper limit of normal (ULN) (unless increase is due to hemolysis or a congenital disorder); serum transaminases (SGPT and/or SGOT) \</= 2.5 \* ULN.
6. Cardiac ejection fraction \>/= 45% (by either echocardiography or MUGA scan).
7. Ability to understand and provide signed informed consent.

Exclusion Criteria:

1. Patients with acute promyelocytic leukemia (APL).
2. Any coexisting medical condition that in the judgment of the treating physician is likely to interfere with study procedures or results.
3. Nursing women, women of childbearing potential with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception (such as birth control pills, intrauterine device (IUD), diaphragm, abstinence, or condoms by their partner) over the entire course of therapy.
4. Active and uncontrolled infection requiring therapy with IV antibiotics or antifungal therapy. Prior or concurrent history of one or more opportunistic infections (e.g., cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB).
Locations (1)
  • Houston, Texas, United States